DURHAM, N.C., Sept. 6, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at the Stifel Nicolaus 2011 Healthcare Conference being held September 7-9, 2011 at the Four Seasons Hotel in Boston, Massachusetts. The Stifel Nicolaus Healthcare Conference showcases presentations from established and emerging public and private companies, including those engaged in biotechnology, diagnostics, healthcare IT & services, life science technology, major and specialty pharmaceuticals, and medical devices.
Mr. Moch's presentation, scheduled for Friday, September 9 at 8:00 am ET in the Winthrop Room, will include an update on the company's clinical pipeline, which includes CMX001. CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of dsDNA viruses, including herpes viruses, adenoviruses, and orthopox viruses. In addition, CMX001 is being developed as a potential countermeasure in the event of a smallpox release.
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.
The company's lead candidate, CMX001, is being developed as a potential broad spectrum, oral antiviral agent for the treatment or prevention of life-threatening double-stranded DNA (dsDNA) viral diseases. To date, more than 550 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols, including over 250 individuals who have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved